Showing posts with label TGen. Show all posts
Showing posts with label TGen. Show all posts

TGen-Scottsdale Healthcare researchers make breakthrough in lung cancer



[Source: TGen] - Researchers for TGen Clinical Research Services at Scottsdale Healthcare (TCRS) have identified a way to predict which patients with small-cell lung cancer may be resistant to first-line chemotherapy.

The study, Tumor MicroRNA Biomarkers Associated with De Novo Chemoresistance in Small Cell Lung Cancer, will be presented today in San Diego at a joint conference of the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC).

This breakthrough is critical since patients with small-cell lung cancer (SCLC) often do not get a second chance at therapies to combat this aggressive type of cancer.

Circumcision associated with significant changes in bacteria


[Source: TGen] - Circumcision, which substantially lowers HIV risk in men, also dramatically changes the bacterial communities of the penis, according to a study led by scientists at the Translational Genomics Research Institute (TGen) and Johns Hopkins University and published Jan. 6 in the scientific journal PLoS ONE.

And these bacterial changes may also be associated with earlier observations that women whose male partners are circumcised are less likely to develop bacterial vaginosis, an imbalance between good and harmful bacteria.

The study - The Effects of Circumcision on the Penis Microbiome - could lead to new non-surgical HIV preventative strategies for the estimated 70 percent of men worldwide (more than 2 billion) who, because of religious or cultural beliefs, or logistic or financial barriers, are not likely to become circumcised.

For more information: Circumcision associated with significant changes in bacteria

The Effects of Circumcision on the Penis Microbiome

Price LB, Liu CM, Johnson KE, Aziz M, Lau MK, et al. 2010 The Effects of Circumcision on the Penis Microbiome. PLoS ONE 5(1): e8422. doi:10.1371/journal.pone.0008422


TGen analysis identifies biomarkers for diabetic kidney failure


[Source: TGen] - Researchers using a DNA analysis tool developed by the Translational Genomics Research Institute (TGen) and UCLA have identified genetic markers that could help treat chronic kidney disease among diabetics.

Study results, published in the December edition of Diabetic Medicine, show it is possible to identify biomarkers associated with end-stage renal disease (ESRD) from the pooled DNA of more than 1,000 diabetics. Specifically, TGen researchers identified genes that could potentially contribute to ESRD among those with Type 1 Diabetes.

ESRD almost always follows chronic kidney failure and although treatable with dialysis or transplantation, mortality rates remain high. While diabetic kidney disease is one of the most common complications of diabetes, it is currently not possible to determine who is at risk for ESRD.

For more information: TGen analysis identifies biomarkers for diabetic kidney failure


Scottsdale Healthcare is world’s first site to test new drug

[Source: Scottsdale Healthcare] - TGen Clinical Research Services at Scottsdale Healthcare (TCRS) is the world’s first clinical trials site for a new drug designed to halt cancer cell division.

NMS-1286937 is produced by Nerviano Medical Sciences of Milan, Italy’s largest pharmaceutical research and development facility. NMS-1286937 is designed to stop cancer from spreading by preventing mitosis, the process of cell division.

For more information: Scottsdale Healthcare is world’s first site to test new drug by major Italian pharmaceutical firm

TGen Education and Outreach - Life: It’s Variations of A Theme

1000 Genomes Project provides an in-depth look across multiple genomes

A new international effort – the 1000 Genomes Project – aims to sequence, or spell out, the complete genomes of more than 1,000 individuals, establishing by far the most detailed catalogue of human genetic variation as a tool for medical research.

Full Story: TGen Education and Outreach - Life: It’s Variations of A Theme

Using technology licensed from the Translational Genomics Research Institute, and expertise and resources provided by the Phoenix-based nonprofit Catapult Bio, a Virginia startup firm has unveiled new genomic-analysis techniques to enhance dramatically the capabilities of forensic investigators.

READ MORE

TGen seeks emergency FDA approval of new swine flu test

[Source: TGen] - The Phoenix-based non-profit Translational Genomics Research Institute (TGen) announced today that, along with a business collaborator, it will submit a request to the U.S. Food and Drug Administration for emergency use of a new test to diagnose the 2009 H1N1 swine flu virus.

Details about TGen’s test will be presented Sunday (Nov. 1) at the 47th annual meeting of the Infectious Diseases Society of America (IDSA), being held today through Sunday (Oct. 29-Nov. 1) in Philadelphia.

The new test, developed at TGen’s Pathogen Genomics Division (TGen North) in Flagstaff, can not only detect influenza — as some tests do now — but also can quickly inform doctors about what strain of flu it is and whether or not it may be resistant to oseltamivir (sold under the brand name Tamiflu®; Roche), the primary anti-viral drug on the market to treat H1N1.

For more information: TGen seeks emergency FDA approval of new swine flu test
top